Gastrointestinal flora and gastrointestinal status in children with autism--comparisons to typical children and correlation with autism severity

James B Adams, Leah J Johansen, Linda D Powell, David Quig, Robert A Rubin, James B Adams, Leah J Johansen, Linda D Powell, David Quig, Robert A Rubin

Abstract

Background: Children with autism have often been reported to have gastrointestinal problems that are more frequent and more severe than in children from the general population.

Methods: Gastrointestinal flora and gastrointestinal status were assessed from stool samples of 58 children with Autism Spectrum Disorders (ASD) and 39 healthy typical children of similar ages. Stool testing included bacterial and yeast culture tests, lysozyme, lactoferrin, secretory IgA, elastase, digestion markers, short chain fatty acids (SCFA's), pH, and blood presence. Gastrointestinal symptoms were assessed with a modified six-item GI Severity Index (6-GSI) questionnaire, and autistic symptoms were assessed with the Autism Treatment Evaluation Checklist (ATEC).

Results: Gastrointestinal symptoms (assessed by the 6-GSI) were strongly correlated with the severity of autism (assessed by the ATEC), (r = 0.59, p < 0.001). Children with 6-GSI scores above 3 had much higher ATEC Total scores than those with 6-GSI-scores of 3 or lower (81.5 +/- 28 vs. 49.0 +/- 21, p = 0.00002).Children with autism had much lower levels of total short chain fatty acids (-27%, p = 0.00002), including lower levels of acetate, proprionate, and valerate; this difference was greater in the children with autism taking probiotics, but also significant in those not taking probiotics. Children with autism had lower levels of species of Bifidobacter (-43%, p = 0.002) and higher levels of species of Lactobacillus (+100%, p = 0.00002), but similar levels of other bacteria and yeast using standard culture growth-based techniques. Lysozyme was somewhat lower in children with autism (-27%, p = 0.04), possibly associated with probiotic usage. Other markers of digestive function were similar in both groups.

Conclusions: The strong correlation of gastrointestinal symptoms with autism severity indicates that children with more severe autism are likely to have more severe gastrointestinal symptoms and vice versa. It is possible that autism symptoms are exacerbated or even partially due to the underlying gastrointestinal problems. The low level of SCFA's was partly associated with increased probiotic use, and probably partly due to either lower production (less sacchrolytic fermentation by beneficial bacteria and/or lower intake of soluble fiber) and/or greater absorption into the body (due to longer transit time and/or increased gut permeability).

Figures

Figure 1
Figure 1
Comparison of SCFA's for the Autism-Probiotic group, the Autism-No-Probiotic group, and the controls. Note that the Valerate data is magnified 10x so that it is visible on the chart. The stars indicate the degree of significance of the result of a t-test comparison of the level of SCFA's in the autism subgroup (Probiotic or No-Probiotic) vs. the controls - * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 2
Figure 2
Comparison of ATEC subscores for the Autism-Low 6-GSI group (few GI problems) and the Autism High 6-GSI group (many GI problems); the stars indicate the significance (*** p < 0.001, ** p < 0.01).
Figure 3
Figure 3
6-Item Gastrointestinal Severity Index (6-GSI) vs. total ATEC score.

References

    1. Buie T, Fuchs GJ, Furuta GT, Kooros K, Levy J, Lewis JD, Wershil BK, Winter H. Recommendations for evaluation and treatment of common gastrointestinal problems in children with ASDs. Pediatrics. 2010;125(Suppl 1):S19–29. doi: 10.1542/peds.2009-1878D.
    1. Molloy CA, Manning-Courtney P. Prevalence of chronic gastrointestinal symptoms in children with autism and autistic spectrum disorders. Autism. 2003;7(2):165–171. doi: 10.1177/1362361303007002004.
    1. Nikolov Roumen N, Bearss Karen E, Jelle Lettinga, Craig Erickson, Maria Rodowski, Aman Michael G, McCracken James T, McDougle Christopher J, Elaine Tierney, Benedetto Vitiello, Eugene Arnold L, Bhavik Shah, Posey David J, Louise Ritz, Lawrence Scahill. Gastrointestinal Symptoms in a Sample of Children with Pervasive Developmental Disorders. J Autism Dev Disord. 2009;39:405–413. doi: 10.1007/s10803-008-0637-8.
    1. Xue Ming, Michael Brimacombe, Janti Chaaban, Barbie Zimmerman-Bier, Wagner George C. Autism Spectrum Disorders: Concurrent Clinical Disorders. J Child Neurol. 2008;23(1):6–13.
    1. Valicenti-McDermott M, McVicar K, Rapin I, Wershil BK, Cohen H, Shinnar S. Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease. J Dev Behav Pediatr. 2006;27(2 Suppl):S128–36. doi: 10.1097/00004703-200604002-00011.
    1. Adams JB, Holloway CE, George F, Quig D. Analyses of Toxic Metals and Essential Minerals in the Hair of Arizona Children with Autism and their mothers. Biol Tr El Res. 2006;110:193–209. doi: 10.1385/BTER:110:3:193.
    1. Adams JB, Romdalvik J, Ramanujam VMS, Legator MS. Mercury, Lead, and Zinc in Baby Teeth of Children with Autism vs. Controls. J Toxicol Environ Health. 2007;70(12):1046–51. doi: 10.1080/15287390601172080.
    1. Adams JB, Romdalvik J, Levine KE, Hu L-W. Mercury in First-Cut Baby Hair of Children with Autism vs. Typically-Developing Children. Toxicological and Environmental Chemistry. 2008;90(4):739–753. doi: 10.1080/02772240701699294.
    1. Konstantareas MM, Homatidis S. Ear infections in autistic and normal-children. Journal of Autism and Developmental Disorders. 1987;17(4):585–594. doi: 10.1007/BF01486973.
    1. Niehus R, Lord C. Early medical history of children with autism spectrum disorders. Journal of Developmental and Behavioral Pediatrics. 2006;27(2):S120–S127. doi: 10.1097/00004703-200604002-00010.
    1. Finegold SM, Molitoris D, Song Y, Liu C, Vaisanen ML, Bolte E, McTeague M, Sandler R, Wexler H, Marlowe EM, Collins MD, Lawson PA, Summanen P, Baysallar M, Tomzynski TJ, Read E, Johnson E, Rolfe R, Nasir P, Shah H, Haake DA, Manning P, Kaul A. Gastrointestinal microflora studies in late-onset autism. Clinical Infectious Diseases. 2002;35:S6–S16. doi: 10.1086/341914.
    1. Song YL, CX Liu, Finegold SA. Real-time PCR quantitation of clostridia in Feces of autistic children. Applied and Environmental Microbiology. 2004;70(11):6459–6465. doi: 10.1128/AEM.70.11.6459-6465.2004.
    1. Parracho HM, Bingham MO, Gibson GR, McCartney AL. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. Journal of Medical Microbiology. 2005;54(10):987–991. doi: 10.1099/jmm.0.46101-0.
    1. Finegold SM, Dowd SE, Gontcharova V, Liu C, Henley KE, Wolcott RD, Youn E, Summanen PH, Granpeesheh D, Dixon D, Liu M, Molitoris DR, Green JA. Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe. 2010;16(4):444–53. doi: 10.1016/j.anaerobe.2010.06.008.
    1. Sandler RH, Finegold SM, Bolte ER, Buchanan CP, Maxwell AP, Väisänen ML, Nelson MN, Wexler HM. Short-term benefit from oral vancomycin treatment of regressive-onset autism. Journal of Child Neurology. 2000;15(7):429–435. doi: 10.1177/088307380001500701.
    1. Finegold SM. Therapy and epidemiology of autism-clostridial spores as key elements. Medical Hypotheses. 2008;70(3):508–511. doi: 10.1016/j.mehy.2007.07.019.
    1. MacFabe DF, Cain DP, Rodriguez-Capote K, Franklin AE, Hoffman JE, Boon F, Taylor AR, Kavaliers M, Ossenkopp KP. Neurobiological effects of intraventricular propionic acid in rats: Possible role of short chain fatty acids on the pathogenesis and characteristics of autism spectrum disorders. Behav Brain Res. 2007;176(1):149–69. doi: 10.1016/j.bbr.2006.07.025.
    1. Shultz SR, MacFabe DF, Ossenkopp KP, Scratch S, Whelan J, Taylor R, Cain DP. Intracerebroventricular injection of propionic acid, an enteric bacterial metabolic end-product, impairs social behavior in the rat: Implications for an animal model of autism. Neuropharmacology. 2008;54(6):901–911. doi: 10.1016/j.neuropharm.2008.01.013.
    1. Elsden SR, Hilton MG. Volatile acid production from threonine, valine, leucine and isoleucine by clostridia. Arch Microbiol. 1978;117(2):165–72. doi: 10.1007/BF00402304.
    1. Shultz SR, Macfabe DF, Martin S, Jackson J, Taylor R, Boon F, Ossenkopp KP, Cain DP. Intracerebroventricular injections of the enteric bacterial metabolic product propionic acid impair cognition and sensorimotor ability in the Long-Evans rat: further development of a rodent model of autism. Behav Brain Res. 2009;200(1):33–41. doi: 10.1016/j.bbr.2008.12.023.
    1. Horvath K, Perman JA. Autism and gastrointestinal symptoms. Curr Gastroenterol Rep. 2002;4(3):251–8. doi: 10.1007/s11894-002-0071-6.
    1. de Magistris L, Familiari V, Pascotto A, Sapone A, Frolli A, Iardino P, Carteni M, De Rosa M, Francavilla R, Riegler G, Militerni R, Bravaccio C. Alterations of the Intestinal Barrier in Patients With Autism Spectrum Disorders and in Their First-degree Relatives. J Pediatr Gastroenterol Nutr. in press .
    1. Rimland B, Edelson S. Autism Treatment Evaluation Checklist: Statistical Analyses. Autism Research Institute, San Diego, CA; 2000.
    1. Schneider CK, Melmed RD, Barstow LE, Enriquez FJ, Ranger-Moore J, Ostrem JA. Oral human immunoglobulin for children with autism and gastrointestinal dysfunction: a prospective, open-label study. Journal Autism Developmental Disorders. 2006;36(8):1053–64. doi: 10.1007/s10803-006-0141-y.
    1. Reifenstein RW, Gray SJ. The Effect of Adrenocorticotropic Hormone upon the Fecal Lysozyme Titer in Ulcerative Colitis. Gastroenterology. 1951;19(3):547–557.
    1. Van Der Sluys Veer A, Brouwer J, Biemond I, Bohbouth GE, Verspaget HW, Lamers CBHW. Fecal Lysozyme in Assessment of Disease Activity in Inflammatory Bowel Disease. Digestive Diseases and Sciences. 1998;43(3):590–595. doi: 10.1023/A:1018823426917.
    1. Dugad L. Performance Verification of Lysozyme ELISA Test Kit Verification 105. Doctor's Data, Inc. Saint Charles, Illinois; 2007.
    1. Guerrant RL, Araujo V, Soares E, Kotloff K, Lima AAM, Cooper WH, Lee AG. Measurement of Fecal Lactoferrin as a Marker of Fecal Leukocytes. Journal of Clinical Microbiology. 1992;30:1238–1242.
    1. Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB. Fecal Lactoferrin is a Sensitive and Specific Marker in Identifying Intestinal Inflammation. The American Journal of Gastroenterology. 2003;98(6):1309–1314. doi: 10.1111/j.1572-0241.2003.07458.x.
    1. Kayazawa M, Saitoh O, Kojima K, Nakagawa K, Tanaka S, Tabata K, Matsuse R, Uchida K, Hoshimoto M, Hirata I, Katsu K. Lactoferrin in Whole Gut Lavage Fluid as a Marker for Disease Activity in Inflammatory Bowel Disease: Comparison with Other Neutrophil-Derived Proteins. The American Journal of Gastroenterology. 2002;97(2):360–369. doi: 10.1111/j.1572-0241.2002.05470.x.
    1. Fine KD, Ogunji F, George J, Niehaus BA, Guerrant RL. Utility of a Rapid Fecal Latex Agglutination Test Detecting the Neutrophil Protein, Lactoferrin, for Diagnosing Inflammatory Causes of Chronic Diarrhea. The American Journal of Gastroenterology. 1998;93(8):1300–1305. doi: 10.1111/j.1572-0241.1998.413_l.x.
    1. Dugad L, Wu Z. PerformanceVerification of Lactoferrin ELISA Test Kit of Fecal Verification 104. Doctor's Data Inc, Saint Charles, Illinois; 2007.
    1. Kudoh K, Shimizu J, Ishiyama A, Wada M, Takita T, Kanke Y, Innami S. Secretion and Excretion of Immunoglobulin A to Cecum and Feces Differ with Type of Indigestible Saccharides. J Nutr Sci Vitaminol. 1999;45:173–181.
    1. Nishio O, Sakae K, Ishihara Y, Isomura S, Inouye S. Adenovirus Infection and Specific Secretory IgA Responses in the Intestine of Infants. Microbiol Immunol. 1992;36(6):623–631.
    1. Stals F, Walther F, Bruggeman CA. Faecal and Pharyngeal Shedding of Rotavirus and Rotavirus IgA in Children with Diarrhea. Journal of Medical Virology. 1984;14:333–339. doi: 10.1002/jmv.1890140406.
    1. Scerpella EG, Gould SS, Mathewson JJ, DuPont HL. Methods for Detection of an Intestinal Secretory Immunoglobulin A Response to Candida spp. and Their Preliminary Application in Human Immunodeficiency Virus-Infected Patients with Chronic Diarrhea. Clinical and Diagnostic Laboratory Immunology. 1995;2(2):246–248.
    1. Zarling EJ, Ruchim MA. Protein Origin of the Volatile Fatty Acids Iso-Butyrate and Iso-Valerate in Human Stool. J Lab Clin Med. 1987;109:566–70.
    1. Araki Y, Andoh A, Fujiyama Y, Itoh A, Bamba T. In vitro Alterations in Fecal Short Chain Fatty Acids and Organic Anions Induced by the Destruction of Intestinal Microflora under Hypotonic and Aerobic Conditions. Int J Mol Med. 2002;9(6):627–631.
    1. Topping DL, Clifton PM. Short Chain Fatty Acids and Human Colonic Function: Roles of Resistant Starch and Nonstarch Polysaccharides. Physiol Reviews. 2001;81(3):1031–1064.
    1. Garner Catherine E, Stephen Smith, de Lacy Costello Ben, Paul White, Robert Spencer, Probert Chris SJ, Ratcliffe Norman M. Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease. FASEB J. 2007;21:1675–1688. doi: 10.1096/fj.06-6927com.
    1. Collin DP, McCormick PG. Determination of Short Chain Fatty Acids in Stool Ultrafiltrate and Urine. Clin Chem. 1974;20(9):1173–1180.
    1. Collin DP, McCormick PG, Schmitt MG Jr. Quantitative Gas-Chromatographic Determination of Short Chain Fatty Acids in Aqueous Samples. Clin Chem. 1974;20(9):1235–1237.
    1. Lönnerdal B. Nutritional and physiologic significance of human milk proteins. Am J Clin Nutr. 2003;77(6):1537S–1543S.
    1. Edelson S. Parent Ratings of Behavioral Effects of Biomedical Interventions. Autism Research Institute, Publication 34, San Diego, CA; 2010.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel